Table 3.
Impact of Presence of a FRP and Other Factors Within the 3 Years Before HAART Initiation on Subsequent Occurrence of Clinical AIDS or Death Among 596 Men Enrolled in the MACS Using Multivariate Cox Models
| Exposures at HAART Initiation | AIDS Free at HAART (N = 472) |
AIDS at HAART (N = 124) |
||
| aHR* (95% CI) | p Value | aHR† (95% CI) | p Value | |
| Education higher than or equal to college | 1.10 (0.68–1.76) | .70 | 0.92 (0.45–1.89) | .82 |
| Ethnicity = White non-Hispanic (vs others) | 1.36 (0.67–2.79) | .40 | 0.75 (0.28–2.01) | .56 |
| Age (per 10-year increase) | 1.42 (1.02–1.99) | .04 | 1.28 (0.76–2.15) | .36 |
| Nadir CD4+ T-cell count (per 100 cell/mm3 increase)‡ | 0.88 (0.74–1.04) | .13 | 0.94 (0.70–1.26) | .66 |
| Maximum plasma viral load (per 1 log10 copies/mL increase)‡ | 1.94 (1.26–3.00) | <.01 | 1.19 (0.65–2.20) | .57 |
| Nadir Hgb before HAART (per 1 g/dL increase)‡ | 0.86 (0.73–1.01) | .07 | 0.99 (0.82–1.21) | .95 |
| Proportion of FRP visits before HAART >25% (vs ≤25%)‡ | 3.83 (1.86–7.92) | <.01 | 2.44 (1.11–5.37) | .03 |
Notes: aHR = HRs adjusted for variables listed in the table; CI = confidence interval; FRP = frailty-related phenotype; HAART = highly active antiretroviral therapy; Hgb = hemoglobin; HR = hazard ratio.
*
Adjusted HRs for AIDS/death.
†
Adjusted HRs for death only.
‡
Within the 3 years before HAART.